Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
- 24 patients enrolled, with 15 having FLT3 mutations
- 81.8% of evaluable patients showed clinical activity
- 77.8% demonstrated decreased bone marrow blasts
- Median overall survival of 3.48 months vs. historical 2.1 months
- Well-tolerated safety profile with no treatment-related discontinuations
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to two new employees as part of their inducement package. The grants, approved on March 23, 2025, by the compensation committee, allow the purchase of a total of 30,000 shares of common stock.
The stock options will vest quarterly over a four-year period, with 1/16 of the shares vesting each quarter, contingent on continued employment. These awards were issued under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, and comply with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants for new employees.
Biomea Fusion (BMEA) announced Q4 and full year 2024 financial results, highlighting significant progress in its diabetes and obesity programs. The company appointed Mick Hitchcock as Interim CEO and shifted focus exclusively to metabolic disorders, terminating oncology trials. Key highlights include:
The COVALENT-111 study showed promising results for icovamenib in type 2 diabetes, achieving a 1.47% HbA1c reduction in severe insulin deficient patients and 53% increase in C-peptide levels. The drug demonstrated durability and good tolerability with no serious adverse events.
Financial results show cash position of $58.6 million as of December 31, 2024. Net loss was $29.3 million for Q4 2024 and $138.4 million for full year 2024. R&D expenses were $118.1 million for 2024, up from $102.5 million in 2023.
Key 2025 milestones include FDA discussions for late-stage development, 52-week COVALENT-111 data, COVALENT-112 open label data, and BMF-650 IND submission.
Biomea Fusion (NASDAQ: BMEA), a clinical-stage diabetes and obesity medicines company, announced a significant leadership change with board member Mick Hitchcock, Ph.D. appointed as interim CEO, replacing Thomas Butler effective immediately.
Dr. Hitchcock, who has served on Biomea's board since March 2021, brings extensive pharmaceutical experience, including 27 years at Gilead Sciences in various vice president roles and 13 years at Bristol-Myers Squibb. His appointment comes at a important time following positive Phase II data for icovamenib in insulin-deficient patients.
The new interim CEO holds a Ph.D. in microbiology from the University of Melbourne and has significant experience in drug development and commercialization, particularly in antiviral treatments. He currently serves as Past Chair of the University of Nevada, Reno Foundation and as an Adjunct Professor of Microbiology at UNR Medical School.
Biomea Fusion (NASDAQ: BMEA) has presented groundbreaking clinical data for icovamenib, their investigational covalent menin inhibitor, at the ATTD 2025 Conference. The drug demonstrated significant improvement in pancreatic beta-cell function in patients with severe insulin-deficient diabetes.
Key findings include:
- 53% mean increase in C-peptide levels 3 months after the last dose
- Strong correlation between C-peptide increase and HbA1c reduction (r=-0.73, p0.0001)Statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022)
- Enhanced responsiveness to GLP-1-based medicines in preclinical studies
The results suggest icovamenib's potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration and enhancing insulin secretion, with benefits persisting beyond the treatment period. The treatment shows particular promise for severe insulin-deficient diabetes, affecting over 100 million people worldwide.
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The compensation committee approved non-qualified stock options for one new employee to purchase 25,000 shares of common stock on March 3, 2025. The stock options will vest quarterly over four years, with 1/16 of shares vesting each quarter, contingent on continued employment. This grant was made under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, as an inducement for employment.
Biomea Fusion (BMEA) will present new clinical data for its diabetes drug icovamenib at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) in Amsterdam, March 19-22, 2025.
The company will deliver two oral presentations, one poster presentation, and chair a symposium, featuring new findings from the COVALENT-111 study's Expansion Phase. The data demonstrates icovamenib's potential in enhancing beta cell function and providing sustained glycemic control in type 2 diabetes patients, with effects lasting 14 weeks post-treatment.
Previous results showed significant HbA1c reductions after 12 weeks of treatment in patients with insulin-deficient type 2 diabetes uncontrolled on standard therapies. The presentations will include new c-peptide data and preclinical results combining icovamenib with GLP-1 receptor agonists, positioning it as a potential first-in-class, disease-modifying therapy for severe insulin-deficient type 2 diabetes, which affects over 100 million adults worldwide.
Biomea Fusion (NASDAQ: BMEA) announced its strategic transformation into a diabetes and obesity medicines company, focusing on icovamenib development for metabolic disorders. The company will conclude its oncology studies and explore partnerships for these assets.
Key clinical trial results for icovamenib showed:
- 1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
- 1.0% HbA1c reduction in patients on GLP-1-based therapies
- 100% response rate in severely insulin deficient patients at 100mg dose
- Durable effects lasting 14 weeks post-treatment
- Favorable safety profile with no adverse-event related discontinuations
The company plans two clinical trials:
- Phase 2/3 adaptive trial for insulin deficient type 2 diabetes patients
- Phase 2b trial combining icovamenib with GLP-1-based therapy